1977
DOI: 10.1093/jnci/59.1.89
|View full text |Cite
|
Sign up to set email alerts
|

Antibodies to Epstein-Barr Virus in Nasopharyngeal Carcinoma and Other Neoplastic Conditions

Abstract: Sera from patients with nasopharyngeal carcinoma (NPC) or other malignant diseases and from apparently healthy controls were examined for Epstein-Barr virus (EBV) antibodies. A difference existed in the percentage of positive sera among the groups studied. High-titer antibody levels were observed in the NPC group, but no statistical difference was found among other groups of patients and controls. The data reaffirmed the association of EBV with NPC but did not support its etiologic role in the development of o… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

1
2
0

Year Published

1979
1979
2008
2008

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 10 publications
(3 citation statements)
references
References 0 publications
1
2
0
Order By: Relevance
“…IgG directed against the EBV antigens were indeed increased in the NPC group as compared to the healthy controls. These results are in agreement with data on Greek patients [24] and others [9]. It is not surprising that few healthy individuals were found positive for anti-VCA IgG, since it is likely that primary EBV infections (apparent or not) can be followed by a persistent virus carrier state [25].…”
Section: Discussionsupporting
confidence: 90%
“…IgG directed against the EBV antigens were indeed increased in the NPC group as compared to the healthy controls. These results are in agreement with data on Greek patients [24] and others [9]. It is not surprising that few healthy individuals were found positive for anti-VCA IgG, since it is likely that primary EBV infections (apparent or not) can be followed by a persistent virus carrier state [25].…”
Section: Discussionsupporting
confidence: 90%
“…The association of nasopharyngeal carcinoma (NPC) and Epstein-Barr virus (EBV) has been confirmed worldwide by serologic studies of EBV antibodies in NPC cases and controls Henle and Henle, 1976;Lin et al, 1972;de-ThC et al, 1975;Sako et al, 1975;Kottaridis et al, 1977). Both Epstein-Barr virus nuclear antigen (EBNA) and EBV DNA have been identified in tumor tissue from NPC and Burkitt's lymphoma patients but not consistently in tissue from patients with other types of cancer (zur Hausen et al, Wolf et al, 1975a, b; Nonoyama et al, 1973;Huang et al, 1974Huang et al, , 1978Klein et a/., 1974;Andersson-Anvret et al, 1977Glaser et al, 1980).…”
mentioning
confidence: 99%
“…Epstein–Barr virus (EBV) is a human herpes virus that infects B lymphocytes as an asymptomatic lifelong infection 6 . EBV is associated with endemic Burkitt’s lymphoma, nasopharyngeal carcinoma, post‐transplantation lymphoproliferative disease, some T‐cell and natural killer cell lymphomas, HL, gastric carcinoma, breast carcinoma and others 3,4,7–11 …”
mentioning
confidence: 99%